Clinical trials: Hospitalized COVID-19
- Condition Hospitalized COVID-19
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
COVID-19
A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients
The purpose of this study is to assess the safety and efficacy of Alvesco (ciclesonide) Inhalation Aerosol in non hospitalized patients with symptomatic COVID-19 infection in a multicenter, randomized, double-blind, placebo…
- Trial name
- NCT04377711
- Testing
- Ciclesonide
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Covis Pharma S.à.r.l.
COVID-19
A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19
This study is open to adults with mild to moderate symptoms of COVID-19 (coronavirus disease). The purpose of this study is to find out whether a medicine called BI 767551 helps people with COVID-19.
- Trial name
- NCT04822701
- Testing
- BI 767551 intravenous, BI 767551 inhaled
- Where
- 5 sites in United States, Spain
- Volunteers
- 5 people
- Sponsor
- Boehringer Ingelheim
Coronavirus, COVID
A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19
This was a randomized, double-blind, placebo-controlled, 29-day study to assess the efficacy and safety of axatilimab plus standard of care (SOC), compared with placebo plus SOC, in participants with respiratory signs and…
- Conditions
- Coronavirus, COVID, ARDS, Cytokine Storm
- Trial name
- NCT04415073
- Testing
- SNDX-6352
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Syndax Pharmaceuticals
Viral Disease
First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.
It is Phase 1b, 2-part, double-blind, placebo-controlled study to evaluate safety, tolerability, and pharmacokinetics of PF-07304814, in patients hospitalized with SARS-CoV-2 virus infection.
- Trial name
- NCT04535167
- Testing
- PF-07304814
- Where
- 13 sites in United States, Belgium and 2 more
- Volunteers
- 26 people
- Sponsor
- Pfizer
Covid-19
CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients
This is a phase 3, randomized, placebo controlled, double-blind, multicenter, stratified study of CPI-006 plus standard of care (SOC) versus placebo plus SOC in mild to moderately symptomatic hospitalized Covid-19 patients with…
- Trial name
- NCT04734873
- Testing
- CPI-006 2 mg/kg + SOC, CPI-006 1 mg/kg + SOC
- Where
- 91 sites in United States, Argentina and 10 more
- Volunteers
- 46 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
COVID-19 Pulmonary Complications, COVID-19
Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants
The primary objective of this study was to evaluate if the addition of zanubrutinib to supportive care increases the respiratory failure-free survival rate at Day 28 in participants hospitalized for Corona Virus Disease 2019…
- Trial name
- NCT04382586
- Testing
- Zanubrutinib, Supportive Care
- Where
- 10 sites in United States
- Volunteers
- 63 people
- Sponsor
- BeiGene
Severe Pneumonia
Reparixin in COVID-19 Pneumonia - Efficacy and Safety
Phase 2 Study Objectives: efficacy and safety of of Reparixin treatment as compared to the control arm in adult patients with severe COVID-19 pneumonia Phase 3 Study Objectives: efficacy and safety of Reparixin treatment as…
- Trial name
- NCT04794803
- Testing
- Reparixin, Standard of care
- Where
- 4 sites in Brazil, Italy
- Volunteers
- 56 people
- Sponsor
- Dompé Farmaceutici S.p.A
Pneumonia, Viral
Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.
The study objective is to assess Efficacy and safety of Reparixin treatment as compared to placebo (both on top of standard treatment) in adult patients with severe COVID-19 pneumonia.
- Trial name
- NCT04878055
- Testing
- Reparixin
- Where
- 17 sites in United States, Italy
- Volunteers
- 287 people
- Sponsor
- Dompé Farmaceutici S.p.A
Covid19
The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19
The study is a multicenter, adaptive, randomized, double-blinded and placebo-controlled Phase II/III trial, and will be conducted globally.
- Trial name
- NCT04644185
- Testing
- SCTA01
- Where
- 7 sites in United States, Argentina and 5 more
- Volunteers
- 102 people
- Sponsor
- Sinocelltech Ltd.
Covid19
Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure
The primary objectives of this study are to evaluate the safety, tolerability, and efficacy of BGE-175 in participants ≥ 50 years of age hospitalized with documented COVID-19.
- Trial name
- NCT04705597
- Testing
- BGE-175
- Where
- 26 sites in United States, Argentina and 1 more
- Volunteers
- 194 people
- Sponsor
- BioAge Labs, Inc.
COVID-19
Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19
Study D822FC00005 will investigate the Phamacokinetics, Safety and tolerability of Acalabrutinib suspension when delivered via a nasogastric tube and co-administered with a Proton Pump Inhibitor, in the treatment of COVID-19.
- Trial name
- NCT04497948
- Testing
- Acalabrutinib
- Where
- 4 sites in Brazil
- Volunteers
- 9 people
- Sponsor
- Acerta Pharma BV
COVID-19
Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)
The purpose of the study is to determine if Liquid Alpha1-Proteinase Inhibitor (Human) (Liquid Alpha1-PI) plus SMT can reduce the proportion of participants dying or requiring intensive care unit (ICU) admission on or before Day…
- Trial name
- NCT04547140
- Testing
- Liquid Alpha1-Proteinase Inhibitor (Human), Standard Medical Treatment
- Where
- 20 sites in United States, Brazil and 3 more
- Volunteers
- 57 people
- Sponsor
- Grifols Therapeutics LLC
Covid19
Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.
The COMET-TAIL main study evaluated efficacy, safety, and tolerability of IM sotrovimab versus IV sotrovimab in high-risk patients for the treatment of mild/moderate COVID-19.
- Trial name
- NCT04913675
- Testing
- sotrovimab
- Where
- 50 sites in United States, France and 1 more
- Volunteers
- 1,065 people
- Sponsor
- Vir Biotechnology, Inc.
COVID-19
Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.
CALAVI will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.
- Trial name
- CALAVI (NCT04346199)
- Testing
- Acalabrutinib
- Where
- 50 sites in Argentina, Brazil and 12 more
- Volunteers
- 177 people
- Sponsor
- AstraZeneca
Covid19, Corona Virus Infection
A Study of Baricitinib (LY3009104) in Children With COVID-19
The purpose for this study is to determine if the study drug baricitinib is effective and safe in hospitalized pediatric participants with Coronavirus disease 2019 (COVID -19) and to confirm the dose.
- Trial name
- COV-BARRIER (NCT05074420)
- Testing
- Baricitinib
- Where
- 14 sites in United States, Brazil and 2 more
- Volunteers
- 6 people
- Sponsor
- Eli Lilly and Company
COVID-19
Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19
Sotrovimab binds to a conserved epitope on the severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 spike protein outside the receptor-binding motif and has been shown to reduce the risk of hospitalization…
- Trial name
- LUNAR (NCT05305651)
- Testing
- Sotrovimab
- Where
- 8 sites in United Kingdom
- Volunteers
- 217 people
- Sponsor
- GlaxoSmithKline
Pneumonia, COVID-19
A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)
This is a randomized, double-blind, placebo-controlled, multicenter, 28-day study of adult participants hospitalized with COVID-19, with a safety follow-up telephone call at Day 60.
- Conditions
- Pneumonia, COVID-19, Coronavirus
- Trial name
- FITE19 (NCT04439071)
- Testing
- PTC299, SOC
- Where
- 41 sites in United States, Australia and 9 more
- Volunteers
- 189 people
- Sponsor
- PTC Therapeutics
COVID-19
Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults
This Phase III study will assess whether AZD7442 (a combination of 2 mAbs) can safely treat outpatient adults with COVID-19 and prevent either severe COVID-19 or death.
- Trial name
- TACKLE (NCT04723394)
- Testing
- AZD7442
- Where
- 103 sites in United States, Argentina and 13 more
- Volunteers
- 910 people
- Sponsor
- AstraZeneca
Coronavirus Disease 2019 (COVID-19)
A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection
The purpose of this study is to evaluate whether rivaroxaban reduces the risk of a composite endpoint of major venous and arterial thrombotic events, all-cause hospitalization, and all-cause mortality compared with placebo in…
- Trial name
- PREVENT-HD (NCT04508023)
- Testing
- Rivaroxaban, Standard of Care (SOC)
- Where
- 17 sites in United States
- Volunteers
- 1,284 people
- Sponsor
- Janssen Research & Development, LLC
COVID-19, Lung Infection
Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia
A phase 2/3 multi-center randomized, double-blind, parallel arm, placebo- controlled study in Adult Subjects Hospitalized with Severe SARS-CoV-2 Positive Pneumonia to determine the potential of opaganib to improve and/or…
- Trial name
- NCT04467840
- Testing
- Opaganib
- Where
- 57 sites in United States, Brazil and 8 more
- Volunteers
- 475 people
- Sponsor
- RedHill Biopharma Limited